Published in Synapse on September 01, 2007
Overlapping neuronal circuits in addiction and obesity: evidence of systems pathology. Philos Trans R Soc Lond B Biol Sci (2008) 3.48
Reward, dopamine and the control of food intake: implications for obesity. Trends Cogn Sci (2010) 3.48
Obesity and the brain: how convincing is the addiction model? Nat Rev Neurosci (2012) 2.26
Neuroimaging and obesity: current knowledge and future directions. Obes Rev (2011) 2.23
Obesity and addiction: neurobiological overlaps. Obes Rev (2012) 1.99
Inverse association between BMI and prefrontal metabolic activity in healthy adults. Obesity (Silver Spring) (2008) 1.92
Insulin, Central Dopamine D2 Receptors, and Monetary Reward Discounting in Obesity. PLoS One (2015) 1.44
Circulating glucose levels modulate neural control of desire for high-calorie foods in humans. J Clin Invest (2011) 1.42
Dorsal striatum and its limbic connectivity mediate abnormal anticipatory reward processing in obesity. PLoS One (2012) 1.33
Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects. EJNMMI Res (2011) 1.29
Effective connectivity of a reward network in obese women. Brain Res Bull (2009) 1.23
Gain weight by "going diet?" Artificial sweeteners and the neurobiology of sugar cravings: Neuroscience 2010. Yale J Biol Med (2010) 1.22
Relationship of dopamine type 2 receptor binding potential with fasting neuroendocrine hormones and insulin sensitivity in human obesity. Diabetes Care (2012) 1.14
BMI and neuronal integrity in healthy, cognitively normal elderly: a proton magnetic resonance spectroscopy study. Obesity (Silver Spring) (2009) 1.11
A comparison of D2 receptor specific binding in obese and normal-weight individuals using PET with (N-[(11)C]methyl)benperidol. Synapse (2013) 1.07
Intravascular food reward. PLoS One (2011) 1.05
Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesity. Neuroendocrinology (2008) 1.05
Ventral striatum binding of a dopamine D2/3 receptor agonist but not antagonist predicts normal body mass index. Biol Psychiatry (2013) 0.96
Striatal dopamine D2-like receptor correlation patterns with human obesity and opportunistic eating behavior. Mol Psychiatry (2014) 0.96
Dopamine and glucose, obesity, and reward deficiency syndrome. Front Psychol (2014) 0.96
Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity. Neuroimage Clin (2015) 0.93
Roux-en-Y gastric bypass: effects on feeding behavior and underlying mechanisms. J Clin Invest (2015) 0.90
Obesity: pathophysiology and intervention. Nutrients (2014) 0.88
Obesity and the neurocognitive basis of food reward and the control of intake. Adv Nutr (2015) 0.86
Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. Neuroimage (2013) 0.86
Leptin regulates dopamine responses to sustained stress in humans. J Neurosci (2012) 0.86
The overlap between binge eating disorder and substance use disorders: Diagnosis and neurobiology. J Behav Addict (2013) 0.84
Compensatory weight gain due to dopaminergic hypofunction: new evidence and own incidental observations. Nutr Metab (Lond) (2008) 0.83
Emotional Eating Phenotype is Associated with Central Dopamine D2 Receptor Binding Independent of Body Mass Index. Sci Rep (2015) 0.82
Metabolic neuroimaging of the brain in diabetes mellitus and hypoglycaemia. Nat Rev Endocrinol (2012) 0.81
Overeating Behavior and Striatal Dopamine with 6-[F]-Fluoro-L-m-Tyrosine PET. J Obes (2010) 0.81
Weight loss after bariatric surgery normalizes brain opioid receptors in morbid obesity. Mol Psychiatry (2015) 0.81
Should pathological gambling and obesity be considered addictive disorders? A factor analytic study in a nationally representative sample. Drug Alcohol Depend (2015) 0.80
Association analyses for dopamine receptor gene polymorphisms and weight status in a longitudinal analysis in obese children before and after lifestyle intervention. BMC Pediatr (2013) 0.79
Neural vulnerability factors that increase risk for future weight gain. Psychol Bull (2016) 0.79
Associations between dopamine D2 receptor availability and BMI depend on age. Neuroimage (2016) 0.78
Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [(11)C](+)PHNO. Neuropsychopharmacology (2016) 0.78
Prediction of striatal D2 receptor binding by DRD2/ANKK1 TaqIA allele status. Synapse (2016) 0.77
A meta-analysis of the relationship between brain dopamine receptors and obesity: a matter of changes in behavior rather than food addiction? Int J Obes (Lond) (2016) 0.77
Neurogenetic and Neuroimaging Evidence for a Conceptual Model of Dopaminergic Contributions to Obesity. Biol Res Nurs (2015) 0.75
Food and addiction among the ageing population. Ageing Res Rev (2014) 0.75
Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation (2006) 3.12
Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet (2004) 2.91
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A (2010) 2.32
Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol (2008) 2.24
Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol (2008) 2.19
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging (2010) 2.09
Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 2.04
Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation (2008) 1.82
Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J Nucl Med (2010) 1.61
Binge drinking in midlife and dementia risk. Epidemiology (2005) 1.61
Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci (2005) 1.58
The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects. Eur J Nucl Med Mol Imaging (2008) 1.55
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging (2009) 1.49
Brain white matter expansion in human obesity and the recovering effect of dieting. J Clin Endocrinol Metab (2007) 1.46
EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2. Eur J Nucl Med Mol Imaging (2009) 1.45
Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol (2008) 1.31
Characteristics of two telephone screens for cognitive impairment. Dement Geriatr Cogn Disord (2002) 1.31
Effects of working-memory training on striatal dopamine release. Science (2011) 1.30
Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain (2003) 1.29
Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int J Neuropsychopharmacol (2007) 1.27
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord (2008) 1.15
Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl) (2005) 1.14
Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals. Gastroenterology (2010) 1.13
Impulse control disorders and depression in Finnish patients with Parkinson's disease. Parkinsonism Relat Disord (2011) 1.12
Test-retest reliability of (11)C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain. Eur J Nucl Med Mol Imaging (2014) 1.11
Altered dopamine D2 receptor binding in atypical facial pain. Pain (2003) 1.10
Increased brain fatty acid uptake in metabolic syndrome. Diabetes (2010) 1.10
C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse (2009) 1.10
Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer (2002) 1.07
Mesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage (2012) 1.07
Metabolic regulation in progression to autoimmune diabetes. PLoS Comput Biol (2011) 1.06
Validation of [(11) C]ORM-13070 as a PET tracer for alpha2c -adrenoceptors in the human brain. Synapse (2015) 1.05
Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord (2006) 1.05
Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease. Neurosci Biobehav Rev (2002) 1.04
Stress-induced hypertension and increased sympathetic activity in mice overexpressing neuropeptide Y in noradrenergic neurons. Neuroendocrinology (2008) 1.03
Mobile phone affects cerebral blood flow in humans. J Cereb Blood Flow Metab (2006) 1.03
Insular dopamine D2 receptors and novelty seeking personality in Parkinson's disease. Mov Disord (2004) 1.03
Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab (2008) 1.02
Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol Aging (2005) 1.02
Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol (2002) 1.01
Measurement of serotonin 5-HT1A receptor binding using positron emission tomography and [carbonyl-(11)C]WAY-100635-considerations on the validity of cerebellum as a reference region. J Cereb Blood Flow Metab (2006) 1.00
Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J Nucl Med (2013) 1.00
C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo. Prog Neuropsychopharmacol Biol Psychiatry (2009) 1.00
MMP-13 regulates growth of wound granulation tissue and modulates gene expression signatures involved in inflammation, proteolysis, and cell viability. PLoS One (2012) 1.00
Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation. J Alzheimers Dis (2008) 0.98
Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail (2006) 0.98
Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry (2005) 0.97
Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PIB in humans. J Nucl Med (2007) 0.97
Effects of a 902 MHz mobile phone on cerebral blood flow in humans: a PET study. Neuroreport (2003) 0.97
Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol Aging (2012) 0.96
Measurement of GABAA receptor binding in vivo with [11C]flumazenil: a test-retest study in healthy subjects. Neuroimage (2008) 0.96
Midlife sleep characteristics associated with late life cognitive function. Sleep (2013) 0.96
Age-related loss of extrastriatal dopamine D(2) -like receptors in women. J Neurochem (2002) 0.96
The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans. Am J Physiol Endocrinol Metab (2008) 0.95
Striatal dopamine D2/D3 receptor availability correlates with individual response characteristics to pain. Eur J Neurosci (2004) 0.94
Dopaminergic effects of caffeine in the human striatum and thalamus. Neuroreport (2004) 0.94
Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med (2009) 0.94
Positron emission tomography examination of cerebral blood flow and glucose metabolism in young CADASIL patients. Stroke (2004) 0.93
Transgenic mice overexpressing neuropeptide Y in noradrenergic neurons: a novel model of increased adiposity and impaired glucose tolerance. Diabetes (2008) 0.93
Visual assessment of [(11)C]PIB PET in patients with cognitive impairment. Eur J Nucl Med Mol Imaging (2010) 0.93
Dopamine D2 receptor binding in the human brain is associated with the response to painful stimulation and pain modulatory capacity. Pain (2002) 0.93
Sevoflurane and propofol increase 11C-flumazenil binding to gamma-aminobutyric acidA receptors in humans. Anesth Analg (2004) 0.92
Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology (Berl) (2002) 0.92
Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders. Mov Disord (2012) 0.92
Human biodistribution and radiation dosimetry of 11C-(R)-PK11195, the prototypic PET ligand to image inflammation. Eur J Nucl Med Mol Imaging (2009) 0.92
Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. J Nucl Med (2004) 0.91
Coffee drinking in middle age is not associated with cognitive performance in old age. Am J Clin Nutr (2009) 0.91
Extensive abnormality of brain white matter integrity in pathological gambling. Psychiatry Res (2011) 0.90
Uptake of inflammatory cell marker [11C]PK11195 into mouse atherosclerotic plaques. Eur J Nucl Med Mol Imaging (2008) 0.90
Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 0.90
Uptake of [N-methyl-11C]alpha-methylaminoisobutyric acid in untreated head and neck cancer studied by PET. Eur J Nucl Med Mol Imaging (2002) 0.90
Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: a clinical and FDOPA-PET study. Parkinsonism Relat Disord (2008) 0.89
Cognitive slowing in Parkinson's disease is related to frontostriatal dopaminergic dysfunction. J Neurol Sci (2013) 0.89